Back to Search
Start Over
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients.
- Source :
- PLoS ONE; Nov2014, Vol. 9 Issue 11, p1-7, 7p
- Publication Year :
- 2014
-
Abstract
- Background: Multiple sclerosis (MS) likely results from an imbalance between regulatory and inflammatory immune processes. CD39 is an ectoenzyme that cleaves ATP to AMP and has been suggested as a novel regulatory T cells (Treg) marker. As ATP has numerous proinflammatory effects, its degradation by CD39 has anti-inflammatory influence. The purpose of this study was to explore regulatory and inflammatory mechanisms activated in fingolimod treated MS patients. Methods and Findings: Peripheral blood mononuclear cells (PBMCs) were isolated from relapsing-remitting MS patients before starting fingolimod and three months after therapy start. mRNA expression was assessed in ex vivo PBMCs. The proportions of CD8, B cells, CD4 and CD39-expressing cells were analysed by flow cytometry. Treg proportion was quantified by flow cytometry and methylation-specific qPCR. Fingolimod treatment increased mRNA levels of CD39, AHR and CYP1B1 but decreased mRNA expression of IL-17, IL-22 and FOXP3 mRNA in PBMCs. B cells, CD4<superscript>+</superscript> cells and Treg proportions were significantly reduced by this treatment, but remaining CD4<superscript>+</superscript> T cells were enriched in FOXP3<superscript>+</superscript> cells and in CD39-expressing Tregs. Conclusions: In addition to the decrease in circulating CD4<superscript>+</superscript> T cells and CD19<superscript>+</superscript> B cells, our findings highlight additional immunoregulatory mechanisms induced by fingolimod. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 19326203
- Volume :
- 9
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- PLoS ONE
- Publication Type :
- Academic Journal
- Accession number :
- 99733728
- Full Text :
- https://doi.org/10.1371/journal.pone.0113025